Equibles does not estimate personal net worth.
Get an email with a short summary when Definium Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DFTX alertsBrandi L. Roberts is recorded as CFO at Definium Therapeutics, Inc. (DFTX). The newest filing on record that lists Brandi L. Roberts as CFO at Definium Therapeutics, Inc. (DFTX) is dated April 27, 2026. Definium Therapeutics, Inc. reported in an 8-K filed May 27, 2025 that Brandi L. Roberts was appointed Chief Financial Officer, effective June 2, 2025. The proxy statement of Definium Therapeutics, Inc. reports total compensation of $5,116,362 for Brandi L. Roberts in fiscal 2025, including a base salary of $288,750. Brandi L. Roberts has spoken on 6 earnings calls across 1 company, most recently for Definium Therapeutics, Inc. on November 9, 2026. Definium Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Definium Therapeutics, Inc. includes Dr. Roger Crystal (CEO), Dr. Suzanne Bruhn (CEO), JR Rahn (CEO) and 7 others.
“On May 27, 2025, Mind Medicine (MindMed) Inc. (the "Company") announced that its Board of Directors (the "Board") had appointed Brandi L. Roberts as Chief Financial Officer, effective as of June 2, 2025 (the "Effective Date").”
“As of September 30th, 2026, cash, cash equivalents, and investments were approximately $1.05 billion, compared with $411.6 million as of December 31st, 2025. Based on our current operating plan and anticipated milestones, we expect these resources to fund planned operations into 2030.”
“Before reviewing our financial results, I'd like to briefly discuss the financing we completed during the quarter and how it positions DefiniM for the years ahead.”
“Before walking through our financial results, I want to briefly set the context for how we're thinking about capital deployment as we move through an important phase for Definium.”
“Research and development expenses were $117.7 million for the year end of December 31st, 2025, compared to $65.3 million for the year end of December 31st, 2024, representing an increase of $52.4 million.”
“Turning to our financial results for the quarter ended 09/30/2025, we ended the quarter with cash, cash equivalents, and investments totaling $209.1 million. As Rob noted earlier, we successfully completed an underwritten public offering last week, raising $258.9 million in gross proceeds.”
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Definium Therapeutics, Inc. (DFTX) | Chief Financial Officer | $288,750 | $5,116,362 |
